LICENSE AGREEMENTS (Details) € in Thousands				1 Months Ended		3 Months Ended								9 Months Ended
	Aug. 05, 2021 USD ($)	Nov. 30, 2020 USD ($)	Jul. 30, 2020 USD ($)	Jul. 31, 2022 USD ($)	Jun. 30, 2021 USD ($)	Sep. 30, 2022 USD ($)	Sep. 30, 2021 USD ($)	Jun. 30, 2021 USD ($)	Mar. 31, 2021 USD ($)	Mar. 31, 2021 EUR (€)	Dec. 31, 2020 USD ($)	Dec. 31, 2020 EUR (€)	Sep. 30, 2020 USD ($)	Sep. 30, 2022 USD ($)	Sep. 30, 2022 EUR (€)	Sep. 30, 2021 USD ($)
Organization And Basis Of Presentation [Line Items]
License and related revenue						$ 40,000,000	$ 0							$ 40,000,000		$ 6,544,000
Variable consideration						30,000,000								$ 30,000,000
Transaction price											$ 11,200,000
Qilu Pharmaceutical Co., Ltd. | Licensing Agreements
Organization And Basis Of Presentation [Line Items]
Potential milestone payments									$ 23,000,000
License and related revenue					$ 900,000			$ 900,000	2,800,000				$ 11,200,000
Upfront payment			$ 12,000,000						12,000,000
Total milestone payments			$ 23,000,000
Royalty payment, percentage			12.00%
Business combination, milestone payments									3,000,000
University of Zurich
Organization And Basis Of Presentation [Line Items]
Royalty payment obligation, percent														4.00%	4.00%
Third party maximum ownership, percent														10.00%	10.00%
Third party minimum ownership, percent														2.00%	2.00%
Expenses related to achievement of development milestone							$ 500,000				300,000
University of Zurich | Collaborative Arrangement, Revenue Based on Clinical Development Milestone
Organization And Basis Of Presentation [Line Items]
License agreement, amount payable upon achievement of specified milestone														$ 500,000
Micromet AG
Organization And Basis Of Presentation [Line Items]
Royalty payment obligation, percent														3.50%	3.50%
Expenses related to achievement of development milestone									$ 600,000	€ 500	$ 900,000	€ 700
Potential milestone payments														$ 2,400,000	€ 2,400
License agreement, royalty payment, reduction, conditions not met														1.50%	1.50%
License maintenance fees														$ 48,987	€ 50
XOMA Ireland Limited
Organization And Basis Of Presentation [Line Items]
License agreement, amount payable upon achievement of specified milestone														$ 250,000
Royalty payment obligation, percent														2.50%	2.50%
Third party maximum ownership, percent														50.00%	50.00%
Third party minimum ownership, percent														1.75%	1.75%
Roche
Organization And Basis Of Presentation [Line Items]
Other receivable, asset purchase agreement						$ 30,000,000								$ 30,000,000
Payments to company upon execution of the Roche Asset Purchase Agreement				$ 40,000,000
Roche | EBI-031
Organization And Basis Of Presentation [Line Items]
Other receivable, asset purchase agreement				$ 70,000,000
Qilu Pharmaceutical Co., Ltd.
Organization And Basis Of Presentation [Line Items]
Royalty period			12 years
MENA License Agreement | Licensing Agreements
Organization And Basis Of Presentation [Line Items]
Upfront payment		$ 3,000,000
Eczacibasi Pharmaceuticals Marketing Agreement
Organization And Basis Of Presentation [Line Items]
Potential milestone payments	$ 2,000,000
Transaction price	$ 1,500,000
Eczacibasi Pharmaceuticals Marketing Agreement | TURKEY
Organization And Basis Of Presentation [Line Items]
Royalty revenue, percentage	0.30